Overview

Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
0
Participant gender:
All
Summary
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction. The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chinese PLA General Hospital
Treatments:
Glucagon-Like Peptide 1
Liraglutide
Criteria
Inclusion Criteria:

Patients with HF were eligible for the study. Diagnosis of HF was based on an impaired
ejection fraction (<50%).

Exclusion Criteria:

Patients were also excluded for the following reasons: unconscious at presentation;
valvular heart disease, cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; or
renal insufficiency.